Toxoplasmosis and Vision Impairment by Bosman, B.Ec., Dip.Ed., M.Spec.Ed., Lyndel
International Journal of Orientation & Mobility • Volume 6, Number 1, 2013-2014 53
Toxoplasmosis and Vision
Impairment
Lyndel Bosman
This paper examines the current literature about toxoplasmosis, a parasitic disease
affecting approximately one third of the world’s human population. The disease 
causes a range of disorders, among them ophthalmic disorders. Case studies are
used to describe the effect of the disease on functional mobility, and the type of 
orientation and mobility training provided.
Toxoplasmosis is a parasitic disease, 
which occurs as a consequence of the 
Toxoplasma gondi (T.gondii) infection, 
one of the most common parasites in the 
world. It is an obligate intracellular parasite
estimated to have infected over one billion 
people throughout the world (Reynolds, 
Falco, Schechtman, & Pizzimenti, 2012).
In humans, T.gondii can be acquired as 
well as congenital, the latter transmitted 
to the placenta through maternal infection.
Congenital infection can result in
spontaneous abortion, stillbirth, neurological 
disorders, and various ophthalmic disorders.
There have also been several studies which 
have reported an association between 
the Toxoplasma gondi infection and the 
increased risk of schizophrenia (Niebuhr, 
Millikan, Cowan, Yolken, & Li, 2008; 
Selten & Kahn, 2002).
The focus of this literature review is to
examine current research relating to ocular 
toxoplasmosis, including its implication for 
orientation and mobility (O&M), with an 
emphasis on the following aspects of the 
disease:
• the cause, diagnosis, and treatment of 
the parasite in the foetus and infant to
minimise the damage to the retina
• ongoing treatment when the parasite is 
reactivated and the search for a cure to
eliminate toxoplasmosis from cells within
the human body
The toxoplasmosis parasite infects 
animals and birds although the sexual cycle
of the parasite occurs in the small bowel
of cats and as such cats play a major role 
in the spreading of infection in nature. The
research presented reveals the presence
of cats is signifi cantly important in the
transmission of the parasite (Brown, 2011;
Mustafa, Yusof, Norma, Muthusamy, &
Shoib, 2012). Cats transmit the parasite
through their faeces which contain oocysts 
(eggs) that can continue to be active for up to
18 months in moist soil. As such a repository
of the parasite can exist in the environment 
from which other animals can be infected.
Humans can consume water or food 
that has been directly contaminated or eat 
undercooked meat from previously infected 
animals (Brown, 2011; Ng & McCluskey,
2002). A concise outline of the way T.gondii
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infects humans is provided by McLeod et al. 
(2006), whereby it is asserted that three main 
routes can transmit the parasite namely: (i) 
consuming infected or undercooked meat;
(ii) ingesting the oocysts (eggs) of the 
parasite that cats pass on in their faeces,
with contamination coming from cat litter 
or soil (the latter including eating unwashed 
vegetables and fruit, contaminated water, 
working in the garden); and (iii) a mother 
acquiring toxoplasmosis during a pregnancy
and the infection fl owing to the foetus.
Congenitally acquired toxoplasmosis is 
mostly not identifi ed in pregnant women, 
especially if they are immunocompetent 
(have strong immune systems) as the 
presence of the infection in these cases is 
generally asymptomatic i.e., no apparent 
symptoms. Dr Rima McLeod, Professor 
of Opthalmology and Visual Science and 
Paediatrics at the University of Chicago, 
Director of the Toxoplasmosis Centre
and her cohort have conducted extensive
research into the treatment of ocular 
toxoplasmosis, with reference also to studies
in France, which are at the forefront of 
treatment of the disease in utero (McLeod et 
al., 2006; McLeod, Kieffer, Sautter, Hosten,
& Pelloux, 2009; Phan et al., 2008).  
 On the basis of their research,
recommendations include that there should 
be systematic screening for acquired 
toxoplasmosis for all pregnant women in
the USA during prenatal visits. In addition, 
standard practice should include the testing 
of all newborn babies for congenital 
toxoplasmosis and that confi rmation 
of laboratory test results and relevant 
counselling should be part of the process 
(McLeod et al., 2006). The physicians who 
collaborated on the National Collaborative 
Chicago-based Congenital Toxoplasmosis 
study identifi ed that signs, symptoms, and 
recognisable risk factors were absent in
more than 50% of the mothers of children
with congenital toxoplasmosis. The clinical
practise of a doctor asking questions and 
performing physical examinations would 
only have revealed half of the mothers who 
had acquired the disease during pregnancy;
the other half would have been identifi ed 
through blood test screening (McLeod, 
Boyer, Karrison, Kasza, Swisher, Roizen,
Jalbrzikowski, Remington, Heydemann, 
Noble, Mets, Holfels, Withers, Latkany, &
Meier, 2006). McLeod et al. (2006) referred 
to obstetric care in France and Austria
where education about toxoplasmosis and 
screening for the parasite is part of the
regular medical appointments for a mother 
during her pregnancy. As a result the rates
of infection have decreased by more than
half, with monthly blood tests assisting the
early identifi cation of any infection and 
timely treatment to help prevent the parasite
infecting the foetus. Previously, infection
rates in France were quite high as their food 
culture included eating undercooked meat, 
such as steak tartare. The authors maintain
that an early diagnosis allows for timely 
treatment, which can decrease the chances
of ophthalmologic or neurological damage.
Reynolds et al. (2012) consider that there 
should be a range of serological testing, the
primary test being the Sabin-Feldman dye
test. They argue that comprehensive tests are
required as the basic clinical presentation of 
ocular toxoplasmosis can be similar to that 
of other infections, including tuberculosis 
and syphilis.
In Australia there appears no evidence
in literature that advice provided by the
Department of Health in the various States
and Territories with regard to pre natal
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testing includes screening for the presence
of the toxoplasmosis parasite as part of the 
recommended standard blood tests. Given 
the increasing presence of domestic cats 
and wild cats in urban and regional areas, 
the collection of water samples from various 
locations such as dams, rainwater tanks, 
and soil samples from locations of high
food production may provide data useful 
in increasing our understanding of the way
toxoplasmosis parasite is transmitted in
Australia.
A diagnosis of toxoplasmosis in infants 
can often be delayed if its presence is 
asymptomatic. Also if infants are pre 
verbal then they are unable to describe their 
vision. Where symptoms exist they can 
include eye pain, infl ammation, and reduced 
vision, often described as “headlights in a 
fog” (Brown, 2011). The clinical features
may include retinochoriditis (i.e., creamy
white lesions adjacent to scars on the 
retina), scotomas (i.e., diminished visual 
acuity) or fl oaters which are opaque spots 
fl oating in the vitreous fl uid. Major vision 
impairment can be evident from lesions on 
the macular, while lesions in the periphery
may not have an obvious impact on vision.
Delair et al. (2011) recommended the use
of an Amsler Grid on a daily basis for those 
with retinal scars for early detection of 
any reactivation of the parasite; although 
this test may not be useful for detecting 
new lesions outside of the central vision.
A recurrence of ocular toxoplasmosis is 
common in those who have congenital 
toxoplasmosis, especially if untreated as an 
infant, and often occurs during adolescence 
(Phan et al., 2008). The reactivation of the 
infection can also be experienced if a person
is immunocompromised i.e., their immune 
system is in a weakened state such as patients
with HIV or undergoing chemotherapy. 
There appears to be general agreement 
in the research literature as to the current 
drug treatment for the parasite when
detected early. Further, McLeod et al. (2009) 
published additional data from their National 
Congenital Toxoplasmosis Study ( McLeod 
et al., 2006) indicating that treatment during
gestation and within the fi rst year of life,
reduced the potential damage caused by 
the parasite and prevented many adverse 
consequences arising from congenital
toxoplasmosis. Ng and McCluskey (2002)
contend that the requirement for treatment 
and its duration needs to be assessed on an
individual basis, determined by factors such
as the potential threat to vision, state of 
vision in the other eye, and the state of the
patient’s immune system at the time.
A combination of drugs is often used 
to achieve a rapid result, with the use 
of pyriemethamine, sulfadiazine, and 
corticosteroids being a common approach
(Delair et al., 2011). Therapy can range 
from four to six to 12 weeks in patients with
a competent immune system, but patients
with a compromised immune system,
such as those receiving organ transplants
or who have HIV infection may require 
longer term treatment. The use of Bactrim
(sulfamethoxazole and trimethoprim) for a
four to six week period appears to be a safe 
yet effective alternative for the common
approach described (Reynolds et al., 2012).
The desired clinical result is evident 
when the retinal scars are no longer white
and fl uffy in appearance, the vitreous clears,
and the existing scars on the retina develop 
sharp margins (McLeod et al., 2009).
Generally, if a person is immunocompetent,
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i.e., they have a healthy immune system,
the toxoplasmosis parasite can be kept in a 
dormant cyst state, although reactivation can 
still occur often without apparent symptoms,
or symptoms which resemble a fl u. 
Toxoplasmosis and O&M
CASE STUDY A
Sarah*, 22 years of age, was diagnosed 
with toxoplasmosis at age fi ve. Sarah’s 
mothers noticed she would sit down when
going down stairs, frequently bump into 
table corners or doorways, and turn her head 
to the side even though she was reaching for 
objects in front of her. An ophthalmologist 
confi rmed that as a result of toxoplasmosis, 
Sarah experienced central vision loss in
both eyes, blurred vision that was more 
pronounced in her right eye, though her 
peripheral vision remained unaffected.
Refl ecting this diagnosis, functionally 
Sarah experienced depth perception issues, 
had diffi culty recognising faces, would 
look down when walking, and slow down 
considerably when walking from the 
sun into shade or vice versa. Sarah was 
referred to a mobility organisation for O&M
training. Sarah initially received long cane 
training that assisted her to: look up when
walking; use her peripheral vision to scan 
the environment; increase her confi dence 
to walk on uneven surfaces and descend 
stairs; walk confi dently despite the presence 
of sun and shade. Sarah currently uses a 
long cane together with a Miniguide. Sarah 
particularly uses the Miniguide at night when
her vision is signifi cantly reduced to assist in 
the location of objects above waist height. 
Currently, Sarah uses the Miniguide of an
evening to locate overhanging tree branches 
and fence shorelines on her three kilometre
(two mile) walk from work to home.
CASE STUDY B
John*, age 18 years, was diagnosed at 
age nine months with congenitally acquired 
toxoplasmosis. John experienced signifi cant 
scarring on the retina in his right eye with
a visual acuity recently measured at 6/60.
John’s left eye had some scarring in the
periphery of vision, which did not appear 
to impact on his vision. John led an active
childhood on a property in a rural location, 
riding motorbikes, and bicycles, trampolining
etc. He enjoyed reading and was able to read 
books with normal size print. In his early 
teenage years he experienced a signifi cant 
growth spurt during a twelve month period,
at which time the toxoplasmosis parasite
reactivated, presumably due to his immune 
system being under pressure during a time
of intense growth. Despite the use of the
appropriate medication, pyriemethamine,
sulfadiazine, and corticosteroids, scarring 
to the retina resulted to the lower right of 
his central vision with his acuity in that eye
recently measured at 6/9.
From an O&M perspective, John appears 
to have no mobility issues, using his vision
in his left eye effectively. He satisfi es the
vision requirements to retain a driver’s
license in NSW and drives a motor vehicle 
in a safe manner, scanning to the left and 
right in particular. In a classroom setting
John prefers to sit toward the front of the
class so that he can read the blackboard.
John, although able to read size 12 font,
fi nds it easier to read enlarged text on his
laptop screen. John is aware that he needs
to maintain a healthy immune system and 
be conscious of any changes in his vision,
as prompt action may limit any further 
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damage arising from a reactivation of the 
toxoplasmosis parasite.
* Name changed for privacy.
Treatment for Toxoplasmosis
Medications to treat reactivations of 
toxoplasmosis although effective are too 
toxic for long-term use, with side effects 
prevalent and some patients becoming 
hypersensitive to them. The parasite endures 
throughout a person’s life and although 
research for a cure is ongoing, there is 
currently no treatment, which can eliminate 
it from the human system, nor an available 
vaccine. Dr Rima McLeod and her team of 
researchers at the University of Chicago, 
however, have been seeking to develop a 
successful approach using strands of DNA 
with a small peptide, inserted into cells 
which contain the parasite, in an attempt 
to disrupt genetic signals (Lai et al., 2012).
The new treatment was tested in tissue
culture containing infected cells and in live 
mice, artifi cially infected with the parasite. 
It was able to signifi cantly reduce the 
production of a number of distinct proteins 
and it is anticipated that it will eliminate the 
parasite’s genes. 
The epidemiology, existence, and 
treatment of ocular toxoplasmosis continue 
to be researched in a number of studies and 
the search for a defi nitive cure is ongoing. 
Different drug combinations are being 
tested in order to fi nd a safer option than 
conventional therapies, which can be too
toxic over extended periods (Reynolds et 
al., 2012). Given cats are the primary host of 
the T.gondii infection, spreading the parasite
via the eggs in their faeces, further research 
is required to develop a vaccine to prevent 
infection in cats and livestock, thereby 
reducing a signifi cant amount of infections 
in humans, acquired both post natal and in
utero. In addition, systematic screening for 
acquired toxoplasmosis for all pregnant 
women during prenatal visits, would 
contribute to early diagnosis and hence 
treatment, thereby reducing the potential
damaging effects of this disease, as evident 
by the example of improved education and 
standardised prenatal tests in France for the
presence of the toxoplasmosis parasite.
The dissemination of the research arising
from a review of the literature would be
useful if presented in an easy to read leafl et 
format, communicating the important 
aspects of the toxoplasmosis parasitic
disease for prospective parents. This could 
include the methods to minimise risk of 
exposure to the parasite, an outline of the
prenatal test and making the request to your 
doctor and current treatments for parents
to seek out should their child experience 
a reactivation of the ocular disease. As
a parent of a teenager with congenital
ocular toxoplasmosis who experienced a
reactivation of the disease at age 14 years,
easily accessible information as to the
ongoing management of the parasite and the
signs to look for which are associated with
a reactivation may have produced a better 
outcome for my son.
The information contained in this literary
review will form the basis of an information
resource, which will be helpful to those
affected by ocular toxoplasmosis.
References
Brown, G. (2011). Quick recertifi cation 
series. JAAPA : Journal of the American
Academy of Physician Assistants, 24(5),
International Journal of Orientation & Mobility • Volume 6, Number 1, 2013-201458
61-62. Retrieved from http://search.
proquest.com
Delair, E., Latkany, P., Noble, A. G., Rabiah,
P., McLeod, R., & Brezin, A. (2011).
Clinical manifestations of ocular 
toxoplasmosis. Ocular Immunology &
Information,19(2), 91-102.
Lai, B., Witola, W. H., El Bissati, K., 
Zhou, Y., Mui, E., Fomovska, A., & 
McLeod, R. (2012). Molecular target 
validation, antimicrobabial delivery, and 
potential treatment of toxoplasma gondii
infections. Proceedings of the National 
Academy of Sciences 2012. doi:10.1073/
pnas.1208775109
McLeod, R., Boyer, K., Karrison, T., Kasza, 
K., Swisher, C., Roizen, N., Jalbrzikowski, 
J., Remington, J., Heydemann, P., Noble, 
A. G., Mets, M., Holfels, E., Withers, 
S., Latkany, P., & Meier, P. (2006).
Outcome of treatment for congenital 
toxoplasmosis, 1981-2004: The national
collaborative Chicago-based, congenital 
toxoplasmosis study. Clinical Infectious 
Diseases, 42,1383-1394.
McLeod, R., Kieffer, F., Sautter, M.,
Hosten, T., & Pelloux, H. (2009). Why 
prevent, diagnose and treat congenital 
toxoplasmosis? Mem Inst Oswaldo Cruz, 
104(2), 320-344.
Mustafa, M., Yusof, I. M., Norma, Y., 
Muthusamy, P., & Shoib, S. A. (2012). 
Toxoplasmosis: Maternal, pediatric, and 
ocular - need for a change in prevalence.
Science International, 24(1), 69-73.
Retrieved from http://search.proquest.
com/ 
Ng, P., & McCluskey, P. J. (2002). Treatment 
of ocular toxoplasmosis. Australian 
Prescriber, 25(4), 88-90.
Niebuhr, D. W., Millikan, A. M., Cowan,
D. N., Yolken, R., Li, Y., & Weber, N. S.
(2008). Selected infectious agents and 
risk of schizophrenia among U.S. military
personnel. The American Journal of 
Psychiatry, 165(1), 99-106. Retrieved 
from http://search.proquest.com
Phan, L., Kasza, K., Jalbrzikowski, J., 
Noble, A. G., Latkany,P., Kuo, A., Mieler,
W., Meyers, S., Rabiah, P., Boyer, K.,
Swisher, C., Mets, M., Roizen, N., Cezar,
S., Sautter, M., Remington, J., Meier, 
P., & McLeod, R. (2008). Longitudinal
study of new eye lesions in children
with toxoplasmosis who were not treated 
during the fi rst year of life. American
Journal of Ophthalmology, 146(3),
375-384.
Reynolds, S. A., Falco, L. A., Shectman, D. 
L., & Pizzimenti, J. J. (2012). The many
faces of Ocular Toxoplasmosis. Review of 
Optometry, 149(8), 67-72. 
Selten, J. P., & Kahn, R. S. (2002).
Schizophrenia after prenatal exposure to
toxoplasma gondii? Clinical Infectious 
Diseases, 35, 633-634. Retrieved from
http://search.proquest.com
Lyndel Bosman, B.Ec., Dip.Ed., M.Spec.Ed.,
(Sensory Disability), O&M instructor, Guide Dogs
NSW/ACT, Australia; e-mail:< lbosman@guidedogs.
com.au>.
